{"id":"us-ocrevus","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Infections (including serious infections)"},{"rate":null,"effect":"Immunosuppression"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"US-Ocrevus (ocrelizumab biosimilar candidate by Celltrion) binds to CD20 antigen expressed on B lymphocytes, leading to B cell depletion through antibody-dependent cellular cytotoxicity and direct apoptosis. This mechanism reduces pathogenic B cell-mediated autoimmune responses in conditions like multiple sclerosis and certain B-cell malignancies.","oneSentence":"US-Ocrevus is a monoclonal antibody that targets CD20 on B cells, depleting them to reduce autoimmune-mediated inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:53:22.050Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis (relapsing and primary progressive forms)"},{"name":"B-cell non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT07207148","phase":"","title":"People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2025-11-15","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT06700343","phase":"PHASE3","title":"Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-01-13","conditions":"Relapsing-remitting Multiple Sclerosis (RRMS)","enrollment":444},{"nctId":"NCT06847724","phase":"PHASE3","title":"Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"Sandoz","startDate":"2025-06-10","conditions":"Relapsing Multiple Sclerosis","enrollment":175},{"nctId":"NCT05906992","phase":"PHASE3","title":"A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis","status":"RECRUITING","sponsor":"Celltrion","startDate":"2024-01-11","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":512}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ocrelizumab"],"phase":"phase_3","status":"active","brandName":"US-Ocrevus","genericName":"US-Ocrevus","companyName":"Celltrion","companyId":"celltrion","modality":"Biologic","firstApprovalDate":"","aiSummary":"US-Ocrevus is a monoclonal antibody that targets CD20 on B cells, depleting them to reduce autoimmune-mediated inflammation. Used for Multiple sclerosis (relapsing and primary progressive forms), B-cell non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}